Autologous haematopoietic stem cell transplantation in childhood solid tumours

Reports of Practical Oncology and Radiotherapy

Volumn 5, Issue 2, 2000, Pages 49-55

  Koscielniak, Ewa ^a  

^a OLGAHOSPITAL   (Germany)

Author keywords

Autologous transplantation; Childhood malignancies; Stem cell transplantation

Indexed keywords

EID: 36949037913     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1507-1367(00)70362-2     Document Type: Article

References (33)

1. Chen AR. High dose therapy with stem cell rescue for pediatric solid tumors:rationale and results. Pediatr Transplantation 1999; 3, suppl.1: 78-86.
2. Pinkerton CR. ENSG 1 randomized study 0 high dose melphalan in neuroblastoma. Bone Marrow Transplant 1991; 7:112-3.
3. Matthay KK, Villablanca JG, Seeger Re, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165-73.
4. McCowage GB, Vowels MR, Shaw PJ, et al. Autologous bone marrow transplantation for advanced neuroblastoma using teniposide, doxorubicine, melphalan, cisplatin and total body irradiation J Clin Onco11995; 13: 2789-95.
5. Dini G, Lanino E, Garaventa AD, et al. Myeloablative therapy and unpurged autologous bone marrwo transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oneal 1991; 9: 962-9.
6. Philip T, Ladenstein R, Lasset CO. 1070 Myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Registry Solid Tumor Working Party. Eur J Cancer 1997; 33: 2130-5.
7. Ladenstein R, Philip T, Lasset CO, et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry J Clin Onco11998; 16: 953-65.
8. Philip T, Ladenstein R, Zucker JM, et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study Br J Cancer 1993; 67: 119-27.
9. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastoma in children older than 1 year at diagnosis J Clin Oncol 2000; 18: 468-76.
10. Stram DO, Matthay KK, O' Leary M, et al. Consolidation chemoradiothreapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group Studies J Clin Onco11996; 14: 2417-26.
11. Kawa K, Ohnuma N, Kaneka M, et al. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months. J Clin Oncol 1999; 17: 3216-20.
12. Klingebiel Th, Bader P, Beck J, et al. Treatment of neuroblastoma stage 4 with 1311-meta-iodobenzylguanidine, high-dose chemotherapy and immuntherapy. A Pilot study. Eur J Cancer 1998; 34: 1398-402.
13. Kremens B, Hero B, Garte M, et al. Maintenance therapy versus megatherapy as consolidation treatment in stage 4 neuroblastoma Med Pediatr Onco11996; 27: 251.
14. Burdach St, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem cell rescue in poor prognosis Ewing sarcoma. J Clin Oncol 1993; 11: 1482-8. 54
15. Laws HJ, Burdach S, van Kaick B, et al. Multimodality diagnostics and megatherapy in poor prognosis Ewing's tumor patients. A single-center report. Strahlenther Onkol 1999; 175: 488-94.
16. Paulussen M, Ahrens S, Burdacti S; Craft A, Dockhorn-Dworniczak B, Dunst J, Frohlich B, Winkelmann W, Zoubek A, Jürgens H. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies Ann Oncol 1998; 9: 275-81.
17. Valteau-Couanet D, Michon J, Plouvier ED, et al. Treatment of metastatic Ewings's sarcomas with busulfan and melphalan consolidation high dose chemotherapy. A study of the French Society of Pediatric Oncology (SFOP) Med Pediatr Oneal 1999; 27: 238.
18. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total body irradiation and autologous bobe marrow transplant in the treatment of high risk Ewing's sarcoma and rhabdomyosarcoma J Clin Oncol 1993; 11: 1911-8.
19. Ladenstein R, Hartmann O, Pinkerton R, et al. A multivariate and matched pair analysis on high risk Ewing' tumor patients undergoing mgtlscr in Europe. Bone Marrow Transplant 1999; 21: 227.
20. Klingebiel Th, Pertl U, Hess CF, et al. Treatment of children with relapsed soft tissue sarcoma: Report of ethe German CESS/CWS REZ 91 Trial. Med Pediatr Oncol 1998; 30: 269-75.
21. Koscielniak E, Klingebiel T, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the Germani IAustrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19: 227-31.
22. Carli M, Colombatti O, Oberlin O, et al. High dose melphalan with autologous stem-cell rescu in metastatic rhabdomyosarcoma. J Clin Oncol 1999; 17: 2796-803.
23. Koscielniak E. Rosti G, Treuner J, et al. Prognosis in patients with primary bone and/or bone marrow metastases of rhabdomyosarcoma (RMS). A joint report of the EBMT Solid Tumor Working Party and the German Soft Tissue Sarcoma Study (CWS). Bone Marrow Transpl. 1998; 21: 226.
24. Koscielniak E, Rosti G, Hartmann O, et al. 20 yrs experience with high dose chemotherapy in patients with metastatic and recurrent rhabdomyosarcoma. An EBMT Solid Tumor Working Party update 1998, Bone Marrow Transplant 1999; 23: 190.
25. Koscielniak E, Harms 0, Henze G, et al. Results of treatment for soft tissues sarcoma in childhood and adolescence. A final report of the German Cooperative Soft Tissues Sarcoma Study CWS-86. J Clin Oncol 1999; 17: 3706-19.
26. Koscielniak E, Rosti G, Hartmann D., et al. Is more better? Double high dose chemotherapy in patients with metastatic and recurrent rhabdomyosarcoma. Bone Marrow Transplant 2000; 25: 69.
27. Klingebiel, Koscielniak E, PilzT, et al. High dose therapy versus oral maintance: Interim result of HD CWS 96 study for tretament of patients with metastasized soft tissue sarcoma. Bone Marrow Transplant 2000; 25: 245.
28. Oallorso S, Badel-Serra I, Baranzelli MC, et al. High dose therapy (HOT) with stem cell rescue in poor risk Wilms' tumor: an EBMT solid tumor wp rgistry update at June 1997. Bone Marrow Transplant 1998; 21: 230.
29. Pein F, Michon J, Valteau-Couanet 0, et al. High - dose melphalan, etoposide, and carboplatin followed by autologous stem - cell rescue in pe recurrent Wilm's tumor: a French Society of Pediatric Oncology study. J Clin Oncol 1998; 16: 3295-301. Rep. Praet. Oneol. Radiother. 5 (2) 2000
30. Mahoney DH, Strother D, Camitta B, et al. High dose melphalan and cyclophosphamid with bone marrow rescue for recurrent! progressive malignant brain tumros in children: A Pilot Pediatric Oncology Group Study J Clin Onco11996; 14: 382-8.
31. Graham ML, Herndon JE, Casey IIJR, et al. High dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high risk pediatric brain tumors. J Clin Oncol 1997; 15: 181423.
32. Gururangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16: 2486-93.
33. Bouffet E, Raquin M, Doz F, et al. Radiotherapy followed by high dose busulfan and thiotepa. A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 2000; 88: 685-92.